A Phase 3 interventional study of Sitagliptin plus metformin and Placebo to metformin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-09-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 66th largest by enrollment of the 197 interventional ones that give a count, is one of 13 that started in 2011, is one of 74 in phase 3, and was the 128th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 13 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 223 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 79th largest by enrollment of the 170 interventional ones that give a count, is one of 10 that started in 2011, is one of 86 in phase 3, and was the 145th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effect of the addition of sitagliptin (administered as MK-0431A or MK-0431A XR) relative to the addition of placebo on glycated hemoglobin (A1C), and the safety and tolerability of the addition of sitagliptin, in pediatric participants (ages 10-17 years) with type 2 diabetes mellitus with inadequate glycemic control on metformin therapy (alone or in combination with insulin). The primary hypothesis is that the addition of sitagliptin reduces glycated hemoglobin (A1C) more than the addition of placebo after 20 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For MK-0431A-170 base study and MK-0431A-289:
For MK-0431A-170 extension protocol:
Exclusion Criteria:
For MK-0431A-170 base study and MK-0431A-289:
For MK-0431A-170 extension protocol:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.
Drug: Sitagliptin plus metformin · Drug: Placebo to metformin · Drug: Insulin
Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.
Drug: Metformin · Drug: Placebo to sitagliptin plus metformin · Drug: Insulin
Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.
Drug: Sitagliptin plus metformin XR · Drug: Placebo to metformin XR · Drug: Insulin
Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.
Drug: Insulin · Drug: Placebo to sitagliptin plus metformin XR · Drug: Metformin XR
Drug pages: Sitagliptin · Metformin
Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1700 mg or 2000 mg of metformin. Dosage of metformin was based on each participant's daily metformin dose prior to enrollment.
Also known as: MK-0431A
Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to metformin.
Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 1000 mg, 1700 mg or 2000 mg of metformin. Dosage was based on each participant's daily metformin dose prior to enrollment.
Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to sitagliptin plus metformin.
Also known as: Placebo to MK-0431A
Drug pages: Sitagliptin · Metformin
Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1500 mg or 2000 mg of metformin. Dosage of metformin XR was based on each participant's daily metformin dose prior to enrollment.
Also known as: MK-0431A XR
Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to metformin XR.
Participants who met protocol-specific glycemic rescue criteria received insulin as glycemic rescue therapy; participants on background insulin had their insulin dose increased for glycemic rescue. During Weeks 20-54, for participants who were not on background insulin or rescued with insulin during Weeks 0-20 in the "Sitagliptin/Metformin" and "Metformin" arms (protocol MK-0431A-170), and during Weeks 0-54 for participants not on background insulin in the "Sitagliptin/Metformin XR" and "Metformin XR" arms (protocol MK-0431A-289), the type of insulin for glycemic rescue was specified to be insulin glargine.
Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to sitagliptin plus metformin XR.
Also known as: Placebo to MK-0431A XR
Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 1000 mg, 1500 mg or 2000 mg of metformin XR. Dosage was based on each participant's daily metformin dose prior to enrollment.
Change From Baseline in A1C at Week 20
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline at Week 20 was estimated from a longitudinal data analysis model.
Time frame: Baseline and Week 20
Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-20
The number of participants experiencing ≥1 adverse event during Weeks 0-20 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to Week 20
Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-20
The number of participants who discontinued from study drug due to an adverse event during Weeks 0-20 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to Week 20
Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56
The number of participants experiencing ≥1 adverse event during Weeks 0-56 were reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to approximately Week 56
Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-54
The number of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to Week 54
Change From Baseline in A1C at Week 54
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline at Week 54 was estimated from a longitudinal data analysis model.
Time frame: Baseline and Week 54
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20
Blood glucose was measured on a fasting basis. Mean change from baseline at Week 20 was estimated from a longitudinal data analysis model.
Time frame: Baseline and Week 20
Change From Baseline in FPG at Week 54
Blood glucose was measured on a fasting basis. Mean change from baseline at Week 54 was estimated from a longitudinal data analysis model.
Time frame: Baseline and Week 54
Percentage of Participants With A1C at Goal (<7.0%) at Week 20
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<7.0%) at Week 20 was presented.
Time frame: Week 20
Percentage of Participants With A1C at Goal (<6.5%) at Week 20
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<6.5%) at Week 20 was presented.
Time frame: Week 20
Percentage of Participants With A1C at Goal (<7.0%) at Week 54
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<7.0%) at Week 54 was presented.
Time frame: Week 54
Percentage of Participants With A1C at Goal (<6.5%) at Week 54
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<6.5%) at Week 54 was presented.
Time frame: Week 54
Percentage of Participants Initiating Glycemic Rescue Therapy by Week 20
Percentage of participants who initiated glycemic rescue therapy prior to Week 20 was reported.
Time frame: Up to Week 20
Percentage of Participants Initiating Insulin Glargine During Weeks 20-54
Percentage of participants who initiated insulin glargine therapy from Weeks 20 through 54 was reported.
Time frame: Week 20 up to Week 54
Baseline A1C
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.
Time frame: Baseline
The study recruited participants in clinics/clinical offices in 28 countries. One participant who was randomized to the arm "Sitagliptin/Metformin" withdrew prior to treatment, then was re-randomized into the study. Only the second randomization is counted for Participant Flow and All-Cause Mortality, so this participant is not counted twice.
| Milestone | Sitagliptin/Metformin | Metformin | Sitagliptin/Metformin XR | Metformin XR |
|---|---|---|---|---|
| Started | 62 | 62 | 47 | 51 |
| Treated | 62 | 62 | 45 | 51 |
| Completed | 59 | 62 | 42 | 47 |
| Not completed | 3 | 0 | 5 | 4 |
| Withdrew: Consent withdrawn by parent/guardian | 0 | 0 | 1 | 3 |
| Withdrew: Withdrawal by subject | 2 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 1 |
| Withdrew: Randomized but not treated | 0 | 0 | 2 | 0 |
| Milestone | Sitagliptin/Metformin | Metformin | Sitagliptin/Metformin XR | Metformin XR |
|---|---|---|---|---|
| Started | 28 | 30 | 42 | 47 |
| Completed | 25 | 28 | 39 | 43 |
| Not completed | 3 | 2 | 3 | 4 |
| Withdrew: Consent withdrawn by parent/guardian | 1 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 2 |
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline at Week 20 was estimated from a longitudinal data analysis model.
| Percentage of glycated hemoglobin | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|
| Change From Baseline in A1C at Week 20 | -0.58 (-0.94 to -0.22) | -0.09 (-0.43 to 0.26) |
The number of participants experiencing ≥1 adverse event during Weeks 0-20 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Participants | Sitagliptin/Metformin | Metformin | Sitagliptin/Metformin XR | Metformin XR | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|---|---|---|---|
| Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-20 | 42 | 46 | 29 | 30 | 71 | 76 |
The number of participants who discontinued from study drug due to an adverse event during Weeks 0-20 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Participants | Sitagliptin/Metformin | Metformin | Sitagliptin/Metformin XR | Metformin XR | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-20 | 1 | 2 | 2 | 2 | 3 | 4 |
The number of participants experiencing ≥1 adverse event during Weeks 0-56 were reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Participants | Sitagliptin/Metformin | Metformin | Sitagliptin/Metformin XR | Metformin XR | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|---|---|---|---|
| Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56 | 26 | 27 | 36 | 39 | 62 | 66 |
The number of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Participants | Sitagliptin/Metformin | Metformin | Sitagliptin/Metformin XR | Metformin XR | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-54 | 1 | 1 | 1 | 3 | 2 | 4 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline at Week 54 was estimated from a longitudinal data analysis model.
| Percentage of glycated hemoglobin | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|
| Change From Baseline in A1C at Week 54 | 0.35 (-0.48 to 1.19) | 0.73 (-0.08 to 1.54) |
Blood glucose was measured on a fasting basis. Mean change from baseline at Week 20 was estimated from a longitudinal data analysis model.
| mg/dL | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20 | -2.5 (-16.7 to 11.7) | 8.3 (-5.0 to 21.6) |
Blood glucose was measured on a fasting basis. Mean change from baseline at Week 54 was estimated from a longitudinal data analysis model.
| mg/dL | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|
| Change From Baseline in FPG at Week 54 | 16.8 (-8.4 to 42.0) | 16.9 (-7.0 to 40.8) |
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<7.0%) at Week 20 was presented.
| Percentage of participants | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|
| Percentage of Participants With A1C at Goal (<7.0%) at Week 20 | 43.0 | 31.0 |
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<6.5%) at Week 20 was presented.
| Percentage of participants | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|
| Percentage of Participants With A1C at Goal (<6.5%) at Week 20 | 29.0 | 20.4 |
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<7.0%) at Week 54 was presented.
| Percentage of participants | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|
| Percentage of Participants With A1C at Goal (<7.0%) at Week 54 | 31.4 | 27.3 |
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<6.5%) at Week 54 was presented.
| Percentage of participants | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|
| Percentage of Participants With A1C at Goal (<6.5%) at Week 54 | 18.6 | 19.5 |
Percentage of participants who initiated glycemic rescue therapy prior to Week 20 was reported.
| Percentage of participants | Sitagliptin/Metformin | Metformin | Sitagliptin/Metformin XR | Metformin XR | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|---|---|---|---|
| Percentage of Participants Initiating Glycemic Rescue Therapy by Week 20 | 3.2 | 19.4 | 4.4 | 13.7 | 3.7 | 16.8 |
Percentage of participants who initiated insulin glargine therapy from Weeks 20 through 54 was reported.
| Percentage of participants | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|
| Percentage of Participants Initiating Insulin Glargine During Weeks 20-54 | 22.7 | 26.6 |
Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.
| Percentage of glycated hemoglobin | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|
| Baseline A1C | 7.96 ± 1.11 | 8.06 ± 1.07 |
Collected over Up to 56 weeks for non-serious adverse events. Up to approximately 76 weeks for serious adverse events. Up to approximately 78 weeks for all-cause mortality.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin/Metformin | 1/62 (1.6%) | 4/62 (6.5%) | 34/62 (54.8%) |
| Metformin | 0/62 (0%) | 3/62 (4.8%) | 40/62 (64.5%) |
| Sitagliptin/Metformin XR | 0/47 (0%) | 3/45 (6.7%) | 30/45 (66.7%) |
| Metformin XR | 0/51 (0%) | 3/51 (5.9%) | 36/51 (70.6%) |
| Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | 1/109 (0.9%) | 7/107 (6.5%) | 64/107 (59.8%) |
| Metformin and Metformin XR Pooled | 0/113 (0%) | 6/113 (5.3%) | 76/113 (67.3%) |
| Event | Sitagliptin/Metformin | Metformin | Sitagliptin/Metformin XR | Metformin XR | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/62 | 0/62 | 1/45 | 0/51 | 1/107 | 0/113 |
| GastroenteritisInfections and infestations | 0/62 | 0/62 | 1/45 | 0/51 | 1/107 | 0/113 |
| Upper respiratory tract infectionInfections and infestations | 0/62 | 0/62 | 1/45 | 0/51 | 1/107 | 0/113 |
| Abdominal pain upperGastrointestinal disorders | 0/62 | 0/62 | 0/45 | 1/51 | 0/107 | 1/113 |
| VomitingGastrointestinal disorders | 0/62 | 0/62 | 0/45 | 1/51 | 0/107 | 1/113 |
| H1N1 influenzaInfections and infestations | 0/62 | 0/62 | 0/45 | 1/51 | 0/107 | 1/113 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/62 | 1/62 | 0/45 | 1/51 | 0/107 | 2/113 |
| Suicide attemptPsychiatric disorders | 0/62 | 0/62 | 0/45 | 1/51 | 0/107 | 1/113 |
| Type I hypersensitivityImmune system disorders | 1/62 | 0/62 | 0/45 | 0/51 | 1/107 | 0/113 |
| PyelonephritisInfections and infestations | 1/62 | 0/62 | 0/45 | 0/51 | 1/107 | 0/113 |
| Event | Sitagliptin/Metformin | Metformin | Sitagliptin/Metformin XR | Metformin XR | Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled | Metformin and Metformin XR Pooled |
|---|---|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 10/62 | 6/62 | 9/45 | 10/51 | 19/107 | 16/113 |
| HeadacheNervous system disorders | 3/62 | 8/62 | 2/45 | 10/51 | 5/107 | 18/113 |
| Upper respiratory tract infectionInfections and infestations | 9/62 | 6/62 | 5/45 | 3/51 | 14/107 | 9/113 |
| DiarrhoeaGastrointestinal disorders | 7/62 | 4/62 | 1/45 | 3/51 | 8/107 | 7/113 |
| NasopharyngitisInfections and infestations | 7/62 | 7/62 | 1/45 | 2/51 | 8/107 | 9/113 |
| PharyngitisInfections and infestations | 1/62 | 3/62 | 1/45 | 5/51 | 2/107 | 8/113 |
| Abdominal painGastrointestinal disorders | 2/62 | 4/62 | 4/45 | 4/51 | 6/107 | 8/113 |
| NauseaGastrointestinal disorders | 2/62 | 5/62 | 4/45 | 2/51 | 6/107 | 7/113 |
| GastroenteritisInfections and infestations | 5/62 | 3/62 | 3/45 | 2/51 | 8/107 | 5/113 |
| Urinary tract infectionInfections and infestations | 0/62 | 5/62 | 3/45 | 1/51 | 3/107 | 6/113 |
The baseline characteristics data are presented for all treated participants.
| Age, Continuous(years) | Sitagliptin/Metformin | Metformin | Sitagliptin/Metformin XR | Metformin XR | Total |
|---|---|---|---|---|---|
| Mean | 14.4 ± 2.2 | 13.9 ± 1.8 | 14.8 ± 1.9 | 14.9 ± 1.6 | 14.4 ± 1.9 |
| Age, Customized(Participants) | Sitagliptin/Metformin | Metformin | Sitagliptin/Metformin XR | Metformin XR | Total |
|---|---|---|---|---|---|
| In utero | 0 | 0 | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 | 0 | 0 |
| Children (2-11 years) | 10 | 7 | 3 | 1 | 21 |
| Adolescents (12-17 years) | 52 | 55 | 42 | 50 | 199 |
| Adults (18-64 years) | 0 | 0 | 0 | 0 | 0 |
| From 65-84 years | 0 | 0 | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Sitagliptin/Metformin | Metformin | Sitagliptin/Metformin XR | Metformin XR | Total |
|---|---|---|---|---|---|
| Female | 41 | 40 | 32 | 32 | 145 |
| Male | 21 | 22 | 13 | 19 | 75 |
| Ethnicity (NIH/OMB)(Participants) | Sitagliptin/Metformin | Metformin | Sitagliptin/Metformin XR | Metformin XR | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 23 | 23 | 11 | 20 | 77 |
| Not Hispanic or Latino | 35 | 36 | 29 | 28 | 128 |
| Unknown or Not Reported | 4 | 3 | 5 | 3 | 15 |
| Race (NIH/OMB)(Participants) | Sitagliptin/Metformin | Metformin | Sitagliptin/Metformin XR | Metformin XR | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 3 | 9 | 13 |
| Asian | 21 | 22 | 15 | 6 | 64 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 0 | 2 |
| Black or African American | 2 | 2 | 2 | 4 | 10 |
| White | 24 | 23 | 22 | 27 | 96 |
| More than one race | 14 | 13 | 3 | 5 | 35 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Glycated Hemoglobin (A1C)(Percentage) | Sitagliptin/Metformin | Metformin | Sitagliptin/Metformin XR | Metformin XR | Total |
|---|---|---|---|---|---|
| Mean | 8.02 ± 1.22 | 8.13 ± 1.08 | 7.87 ± 0.94 | 7.97 ± 1.05 | 8.0 ± 1.1 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Dec 2011 to primary completion in Sep 2019, 93 months.
Results were first posted in Oct 2020, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 93 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitagliptin · Metformin